Chemotherapy-Resistant Breast Cancer: BEAUTY2 Study

Judy C. Boughey, M.D.

BEAUTY2 Study Co-Chair

Matthew P. Goetz, M.D.

BEAUTY2 Study Co-Chair

The Breast Cancer Genome-Guided Therapy Study 2 (BEAUTY2) is an exciting group of studies designed to test new drugs for women with chemotherapy-resistant breast cancer. The first drug being tested is abemaciclib — an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) with the brand name Verzenio.

Neoadjuvant chemotherapy is the standard treatment for women with certain types of breast cancer.

For patients with no cancer after standard chemotherapy, the prognosis is excellent. However, for patients with residual cancer after standard chemotherapy, additional therapy to eradicate disease may reduce the risk of future breast cancer events.

Abemaciclib has been approved in the U.S. by the Food and Drug Administration for the treatment of metastatic breast cancer that is resistant to estrogen-targeted therapies. Based on scientific findings from the first BEAUTY study, BEAUTY2 is testing the effects of abemaciclib in patients who have tumors that are estrogen receptor negative and who have residual disease after neoadjuvant chemotherapy.

Participation

All women with triple-negative invasive breast cancer treated with anthracycline- and taxane-based chemotherapy are eligible to participate in this trial, as long as they:

  • Have completed chemotherapy and not yet had surgery
  • Are not pregnant or breast-feeding

After completion of standard chemotherapy, each participant will be assessed by breast imaging and a breast biopsy to see how well the tumor has responded to the chemotherapy treatment. Participants with disease remaining will be treated with abemaciclib, which has shown promise for treating triple-negative breast cancer that is resistant to chemotherapy. Participants who have no or minimal residual disease, as determined by the imaging and biopsy, will proceed to surgery.

View a complete list of preregistration and registration inclusion and exclusion criteria.

Overview of BEAUTY2 study

Contact

Patients and referring physicians can contact the Clinical Trials Referral Office at Mayo Clinic for more information at 855-776-0015 (toll-free).

Contact form

BEAUTY2 study clinical trial page

BEAUTY2 brochure

You can also contact the Center for Individualized Medicine for information on other studies and trials.